Development of FIV-specific cytolytic T-lymphocyte responses in cats upon immunisation with FIV vaccines

Veterinary Microbiology

Volumn 57, Issue 1, 1997, Pages 1-11

  Tellier, Marinka C ^a   Soos, Jeanne ^a   Pu, Ruiyu ^a   Pollock, David ^a   Yamamoto, Janet K ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAT; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FELINE IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNIZATION; NONHUMAN; PROPHYLAXIS; PROTECTION; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; ANTIGENS, VIRAL; CATS; CD4-CD8 RATIO; CYTOTOXICITY, IMMUNOLOGIC; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; IMMUNITY, CELLULAR; IMMUNIZATION; IMMUNODEFICIENCY VIRUS, FELINE; T-LYMPHOCYTES; VIRAL VACCINES;

ANIMALIA; FELIDAE; FELINE IMMUNODEFICIENCY VIRUS; FELIS CATUS;

EID: 0030789052     PISSN: 03781135     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-1135(97)00081-3     Document Type: Article

References (35)

1. Ackley, C.D., Yamamoto, J.K., Levy, N., Pedersen, N.C. and Cooper, M.D., 1990. Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus. J. Virol., 64: 5652-5655.
2. Allison, A.C. and Byars, N.E., 1991. Immunological adjuvants: desirable properties and side-effects. Mol. Immunol., 28: 279-284.
3. Bachmann, M.F., Kundig, T.M., Kalberer, C.P., Hengartner H. and Zinkernagel, R.M., 1993. Formalin inactivation of vesicular stomatitis virus impairs T-cell but not T-help-independent B-cell responses. J. Virol., 67: 3917-3922.
4. Bachmann, M.F., Bast, C., Hengartner, H. and Zinkernagel, R.M., 1994a. Immunogenicity of a viral model vaccine after different inactivation procedures. Med. Microbiol. Immunol. Berl., 183: 95-104.
5. Bachmann, M.F., Kundig, T.M., Freer, G., Li, Y., Kang, C.Y., Bishop, D.H., Hengartner, H. and Zinkernagel, R.M., 1994b. Induction of protective cytotoxic T cells with viral proteins. Eur. J. Immunol., 24: 2128-2236.
6. Bar-Shira-Maymon, B., Michowitz, M., Gibili, O., Klein, O., Pinchasov, A. and Leibovici, J., 1992. Effect of a membrane-active agent on uptake of adriamycin in Lewis lung carcinoma cells derived from primary and metastatic growths. Chemother., 38: 66-73.
7. Baxby, D. and Paoletti, E., 1992. Potential use of non-replicating vectors as recombinants vaccines. Vaccine, 10: 8-9.
8. Becker, Y., 1994. HIV-1 proteins in infected cells determine the presentation of viral peptides by HLA class I and class II molecules and the nature of the cellular and humoral antiviral immune responses - a review. Virus Genes. 8: 249-270.
9. Byars, N.E. and Allison, A.C., 1987. Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity. Vaccine, 5: 223-228.
10. Cox, W., Tartaglia, J. and Paoletti, E., 1993. Induction of cytotoxic T lymphocytes by recombinant canarypox attenuated vaccinia viruses expressing the HIV-1 envelope glycoprotein. Virol., 195: 845-850.
11. Desrosiers, R.C., Wyand, M.S., Kodama, T., Ringler, D.J., Arthur, L.O., Sengal, P.K., Letvin, N.L., King, N.W. and Daniel, M.D., 1989. Vaccine protection against simian immunodeficiency virus infection. Proc. Natl. Acad. Sci. USA, 86: 6353-6357.
12. Flynn, J.N., Cannon, C.A., Beatty, J.A., Mackett, M., Rigby, M.A., Neil J.C. and Jarrett, O., 1994. Induction of feline immunodeficiency virus-specific cytotoxic T cells in vivo with carrier-free synthetic peptide. J. Virol., 68: 5835-5844.
13. Flynn, J.N., Beatty, J.A., Cannon, C.A., Stephens, E.B., Hosie, M.J., Neil, J.C. and Jarrett, O., 1995. Involvement of gag and env specific cytotoxic T lymphocytes in protective immunity to feline immunodeficiency virus. AIDS Res. Hum. Retroviruses, 11: 1107-1113.
14. Fultz, P.N., Nara, P., Barre-Sinoussi, F., Chaput, A., Greenberg, M.L., Muchmore, E., Kieny, M.P. and Girard, M., 1992. Vaccine protection of chimpanzees against challenge with HIV-1 infected peripheral blood mononuclear cells (see comments). Science, 256: 1687-1690.
15. Hariharan, K., Braslawsky, G., Black, A., Raychaudhuri S. and Hanna, N., 1995. The induction of cytotoxic T-cells and tumor-regression by soluble-antigen formulation. Cancer Res., 55: 3486-3489.
16. Hohdatsu, T., Pu, R., Torres, B.A., Trujillo, S., Gardner, M.B. and Yamamoto, J.K., 1993. Passive antibody protection of cats against feline immunodeficiency virus infection. J. Virol., 67: 2344-2348.
17. Hosie, M.J. and Flynn, J.N., 1996. Feline immunodeficiency virus vaccination: Characterization of the immune correlates of protection. J. Virol., 70: 7561-7568.
18. Jarrett, O., Yamamoto, J.K. and Neil, J.C., 1990. Feline immunodeficiency virus as a model for AIDS vaccination. AIDS, 4: s163-s165.
19. Kovacsovics-Bankowski, M., Clark, K., Benacerraf, B. and Rock, K.L., 1993. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl. Acad. Sci. USA, 90: 4942-4946.
20. + cytotoxic T-cells. Vaccine, 12: 73-80.
21. Murphey-Corb, M., Martin, L.N., Davidson-Fairburn, B., Montelaro, R.C., Miller, M., West, M., Ohkawa, S., Baskin, G.B., Zhang, J.Y., Putney, S.D., Allison, A.C. and Eppstein, D.A., 1989. A formalin-inactivated whole SIV vaccine confers protection in macaques. Science, 246: 1293-1297.
22. Perkus, M.E., Limbach, K. and Paoletti, E., 1989. Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J. Virol., 63: 3829-3836.
23. + T lymphocytes of patients with AIDS maintain normal broad cytolytic function despite loss of human immunodeficiency virus specific cytotoxicity. Proc. Natl. Acad. Sci. USA, 87: 4818-4822.
24. Pialoux, G., Excler, J.L., Riviere, Y., Gonzalez-Canali, G., Feuille, V., Coulaud, P., Gluckman, J.C., Matthews, T.J., Meignier, B., Kieny, M.P., Gonnet, P., Diaz, I., Meric, C., Paoletti, E., Tartaglia, J., Salomon, H. and Plotkin, S., 1995. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). AIDS Res. Hum. Retroviruses, 11: 373-381.
25. Piccini, A., Perkus, M.E. and Paoletti, E., 1987. Vaccinia virus as an expression vector. Meth. Enzymology, 153: 545-563.
26. Pu, R., Tellier, M.C. and Yamamoto, J.K., 1995. Mechanism(s) of FIV vaccine protection. Proceedings, The XVIII Symp. Intl. Assoc. Comp. Res. Leukemia Related Dis. Kyoto, Japan.
27. Song, W., Collison, E.W., Billingsley, P. and Brown, W.C., 1992. Induction of feline immunodeficiency virus specific cytolytic T-cell responses from experimentally infected cats. J. Virol., 66: 5409-5417.
28. Tartaglia, J., Jarret, O., Neil, J.C., Desmettre, P. and Paoletti, E., 1993. Protection of cats against feline leukemia virus by vaccination with a canarypoxvirus recombinant, ALVAC-FL. J. Virol., 67: 2370-2375.
29. Vowels, B.R., Gershwin, M.E., Gardner, M.B., Ahmed-Ansari, A. and Mcgraw, T.P., 1989. Characterization of simian immunodeficiency virus-specific T-cell-mediated cytotoxic responses of infected rhesus macaques. AIDS 3: 785-792.
30. Warren, H.S., Vogel, F.R. and Chedid, L.A., 1986. Current status of immunological adjuvants. Annual Rev. Immunol., 4: 369-388.
31. Xiang, T.-X., Chen, X. and Anderson, B.D., 1992. Transport methods for probing the barrier domain of lipid bilayer membranes. Biophys. J., 63: 78-88.
32. Yamamoto, J.K., Sparger, E., Ho, E.W., Andersen, P.H., O'Connor, T.P., Mandell, C.P., Lowenstine, L. and Pedersen, N.C., 1988. Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats. Am. J. Vet. Res., 49: 1246-1258.
33. Yamamoto, J.K., Okuda, T., Ackley, C., Louie, H., Pembroke, E., Zochlinski, Z., Pembroke, E. and Gardner, M.B., 1991a. Experimental vaccine protection against feline immunodeficiency virus. AIDS Res. Hum. Retroviruses, 7: 911-922.
34. Yamamoto, J.K., Ackley, C.D., Zochlinski, H., Louie, H., Pembroke, E., Torten, M., Hansen, H., Munn, R. and Okuda, T., 1991b. Development of IL 2 independent feline lymphoid cell lines chronically infected with feline immunodeficiency virus: importance for diagnostic reagents and vaccines. Intervirol., 32: 361-375.
35. Yamamoto, J.K., Hohdatsu, T., Olmsted, R.A., Pu, R., Louie, H., Zochlinski, H., Acevedo, V., Johnson, H.M., Soulds, G.A. and Gardner, M.B., 1993. Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus. J. Virol., 67: 601-605.